| 摘要 |
Disclosed herein are spiro-cyclopropyl-indolinone compounds, and the use thereof as kinase inhibitors in the treatment of a cancer, such as lung cancer, breast cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiform, ovarian cancer, lymphoma, leukemia, melanoma, sarcoma, paraneoplasia, osteosarcoma, germinoma, glioma and mesothelioma. In one embodiment the compound is (1R,2S)-(E)-5’-fluoro-2-{ 3-(4-(morpholinomethyl)styryl-1H-indazol-6-yl)spiro[cyclopropane-1,3’-indolin]-2’-one 2,2,2-trifluoroacetate. |
